A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
|Articles|February 24, 2022
Daily Medication Pearl: Midodrine Hydrochloride
Author(s)Saro Arakelians, PharmD
Midodrine hydrochloride (Midodrine) treats chronic orthostatic hypotension due to autonomic failure in patients with Bradbury-Eggleston syndrome, Shy-Drager syndrome, diabetes mellitus disease, and Parkinson disease.
Advertisement
Medication Pearl of the Day: Midodrine hydrochloride
Indication: Midodrine hydrochloride (Midodrine) may be used to attenuate symptoms of chronic orthostatic hypotension due to autonomic failure in patients with Bradbury-Eggleston syndrome, Shy-Drager syndrome, diabetes mellitus disease, and Parkinson disease.
Insight:
- Dosing: The usual starting dose of Midodrine is 2.5 mg, 3 times daily.
- Dosage forms: Midodrine is available as 2.5 mg and 5 mg tablets.
- Adverse events: Urinary disturbance, pilomotor reactions and supine hypertension.
- Mechanism of action: Midodrine hydrochloride forms an active metabolite, desglymidodrine, that is an alpha-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
- Manufacturer: AA Pharma
Sources:
https://www.drugs.com/monograph/midodrine.html
Advertisement
Related to this article
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5